Cargando…

180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study

BACKGROUND: In Japanese Guideline for Allergic Rhinitis, drugs for treatment after the start of pollen dispersal are recommended for each type of pollinosis, but drugs for primal therapy are not categorized by the type of pollinosis. We examined the adequacy of different drugs for primal therapy on...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Kimihiro, Gotoh, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513028/
http://dx.doi.org/10.1097/01.WOX.0000411937.90482.89
_version_ 1782251858750865408
author Okubo, Kimihiro
Gotoh, Minoru
author_facet Okubo, Kimihiro
Gotoh, Minoru
author_sort Okubo, Kimihiro
collection PubMed
description BACKGROUND: In Japanese Guideline for Allergic Rhinitis, drugs for treatment after the start of pollen dispersal are recommended for each type of pollinosis, but drugs for primal therapy are not categorized by the type of pollinosis. We examined the adequacy of different drugs for primal therapy on each type of pollinosis. METHODS: Patients with pollinosis attending 11 otorhinolaryngology clinics in Tokyo during part of pollen season (February 18–26) were enrolled and assigned to either an anti-leukotriene agent (pranlukast) or an antihistamine based on their symptoms in the previous year. During 3 months of treatment, symptoms and quality of life (QOL) were investigated by a mail questionnaire at 7 time points (at the start of treatment, and between March 1 and May 15). RESULTS: Of 150 patients with pollinosis who were registered, analysis was conducted on 144 patients (62 receiving anti-leukotriene therapy and 82 receiving antihistamine therapy), excluding those with incomplete questionnaires. In both groups, scores for symptoms of pollinosis and QOL were low, suggesting that both drugs were effective considering the high pollen levels season (5–9 times higher than the previous year). After defining types of pollinosis by the severity of symptoms (sneezing, rhinorrhea, or nasal blockage), stratified analysis was conducted. This showed that antihistamine therapy was effective for the sneezing/rhinorrhea type and anti-leukotriene therapy was effective for the nasal blockage type, with no difference between the 2 drugs the combined type. For the nasal blockage type, symptoms and QOL improved faster with anti-leukotriene than antihistamine therapy from the peak to the end of the pollen season. No adverse effects were observed. CONCLUSIONS: When either an anti-leukotriene (pranlukast) or an antihistamine was used for primal therapy of pollinosis, both drugs improved pollinosis symptoms and QOL. Stratified analysis showed that the antihistamine was more effective for the sneezing/rhinorrhea type and the anti-leukotriene was more effective for the nasal blockage type, with no difference in effectiveness for the combined type. Therefore, appropriate drugs for the type of pollinosis should be selected for primal therapy.
format Online
Article
Text
id pubmed-3513028
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35130282012-12-21 180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study Okubo, Kimihiro Gotoh, Minoru World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: In Japanese Guideline for Allergic Rhinitis, drugs for treatment after the start of pollen dispersal are recommended for each type of pollinosis, but drugs for primal therapy are not categorized by the type of pollinosis. We examined the adequacy of different drugs for primal therapy on each type of pollinosis. METHODS: Patients with pollinosis attending 11 otorhinolaryngology clinics in Tokyo during part of pollen season (February 18–26) were enrolled and assigned to either an anti-leukotriene agent (pranlukast) or an antihistamine based on their symptoms in the previous year. During 3 months of treatment, symptoms and quality of life (QOL) were investigated by a mail questionnaire at 7 time points (at the start of treatment, and between March 1 and May 15). RESULTS: Of 150 patients with pollinosis who were registered, analysis was conducted on 144 patients (62 receiving anti-leukotriene therapy and 82 receiving antihistamine therapy), excluding those with incomplete questionnaires. In both groups, scores for symptoms of pollinosis and QOL were low, suggesting that both drugs were effective considering the high pollen levels season (5–9 times higher than the previous year). After defining types of pollinosis by the severity of symptoms (sneezing, rhinorrhea, or nasal blockage), stratified analysis was conducted. This showed that antihistamine therapy was effective for the sneezing/rhinorrhea type and anti-leukotriene therapy was effective for the nasal blockage type, with no difference between the 2 drugs the combined type. For the nasal blockage type, symptoms and QOL improved faster with anti-leukotriene than antihistamine therapy from the peak to the end of the pollen season. No adverse effects were observed. CONCLUSIONS: When either an anti-leukotriene (pranlukast) or an antihistamine was used for primal therapy of pollinosis, both drugs improved pollinosis symptoms and QOL. Stratified analysis showed that the antihistamine was more effective for the sneezing/rhinorrhea type and the anti-leukotriene was more effective for the nasal blockage type, with no difference in effectiveness for the combined type. Therefore, appropriate drugs for the type of pollinosis should be selected for primal therapy. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3513028/ http://dx.doi.org/10.1097/01.WOX.0000411937.90482.89 Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Okubo, Kimihiro
Gotoh, Minoru
180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study
title 180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study
title_full 180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study
title_fullStr 180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study
title_full_unstemmed 180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study
title_short 180 Selecting Primal Therapy Appropriate for the Type of Pollinosis—Topic-J Study
title_sort 180 selecting primal therapy appropriate for the type of pollinosis—topic-j study
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513028/
http://dx.doi.org/10.1097/01.WOX.0000411937.90482.89
work_keys_str_mv AT okubokimihiro 180selectingprimaltherapyappropriateforthetypeofpollinosistopicjstudy
AT gotohminoru 180selectingprimaltherapyappropriateforthetypeofpollinosistopicjstudy